Faron Historical Balance Sheet
FARN Stock | 165.00 10.00 5.71% |
Trend analysis of Faron Pharmaceuticals Oy balance sheet accounts such as Other Current Liabilities of 2.7 M or Total Current Liabilities of 15.8 M provides information on Faron Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Faron Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Faron Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Faron Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Faron Pharmaceuticals is a good buy for the upcoming year.
Faron Pharmaceuticals Inventory |
|
Faron |
About Faron Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Faron Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Faron Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Faron Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Faron currently owns. An asset can also be divided into two categories, current and non-current.
Faron Pharmaceuticals Balance Sheet Chart
Add Fundamental
Total Current Liabilities
Total Current Liabilities is an item on Faron Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Faron Pharmaceuticals Oy are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Accounts Payable
An accounting item on the balance sheet that represents Faron Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Faron Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Liabilities And Stockholders Equity
The total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation.Most accounts from Faron Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Faron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Faron Pharmaceuticals Oy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Faron Pharmaceuticals' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 10.9 M in 2024, despite the fact that Retained Earnings are likely to grow to (163.6 M).
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 3.5M | 13.3M | 13.1M | 13.8M | Total Assets | 13.2M | 11.3M | 10.2M | 10.5M |
Faron Pharmaceuticals balance sheet Correlations
Click cells to compare fundamentals
Faron Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Faron Pharmaceuticals balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 10.2M | 8.4M | 13.2M | 11.3M | 10.2M | 10.5M | |
Short Long Term Debt Total | 2.8M | 3.2M | 3.5M | 13.3M | 13.1M | 13.8M | |
Other Current Liab | 2.8M | 4.1M | 4.3M | 3.3M | 2.4M | 2.7M | |
Total Current Liabilities | 6.1M | 6.5M | 7.2M | 10.5M | 15.0M | 15.8M | |
Total Stockholder Equity | 1.6M | (1.8M) | 2.9M | (11.5M) | (15.2M) | (14.4M) | |
Net Debt | (4.2M) | (883K) | (3.3M) | 6.3M | 6.2M | 6.5M | |
Retained Earnings | (80.0M) | (96.6M) | (116.3M) | (143.7M) | (172.2M) | (163.6M) | |
Accounts Payable | 3.0M | 2.1M | 2.2M | 5.1M | 9.0M | 9.4M | |
Non Current Assets Total | 1.0M | 996K | 1.2M | 1.5M | 1.4M | 1.3M | |
Long Term Debt | 2.3M | 2.7M | 2.9M | 11.1M | 9.4M | 9.9M | |
Net Receivables | 1.3M | 1.3M | 1.4M | 905K | 1.0M | 981.9K | |
Common Stock Shares Outstanding | 39.9K | 46.8K | 51.8K | 60.1K | 68.8K | 40.5K | |
Liabilities And Stockholders Equity | 10.2M | 8.4M | 13.2M | 11.3M | 10.2M | 10.5M | |
Non Current Liabilities Total | 2.5M | 3.7M | 3.1M | 12.3M | 10.4M | 10.9M | |
Other Current Assets | 2.1M | 3.3M | 5.2M | 2.7M | 2.0M | 2.5M | |
Other Stockholder Equity | 78.8M | 91.9M | (1K) | 129.4M | 154.2M | 161.9M | |
Total Liab | 8.6M | 10.2M | 10.3M | 22.7M | 25.4M | 26.7M | |
Total Current Assets | 9.2M | 7.4M | 12.0M | 9.7M | 8.9M | 9.2M | |
Accumulated Other Comprehensive Income | 78.9K | 92.0K | 116.5K | 129.5K | 154.4K | 162.1K | |
Intangible Assets | 529K | 565K | 899K | 1.2M | 1.1M | 691.5K | |
Net Tangible Assets | 1.1M | (2.4M) | 2.0M | (12.6M) | (11.4M) | (10.8M) | |
Short Long Term Debt | 163K | 122K | 429K | 1.9M | 3.5M | 3.6M | |
Cash | 7.1M | 4.1M | 6.9M | 7.0M | 6.9M | 5.4M | |
Cash And Short Term Investments | 7.1M | 4.1M | 6.9M | 7.0M | 6.9M | 5.4M | |
Property Plant And Equipment Net | 399K | 375K | 207K | 327K | 204K | 195.6K | |
Property Plant And Equipment Gross | 399K | 375K | 207K | 327K | 225K | 198.1K | |
Property Plant Equipment | 399K | 375K | 207K | 327K | 376.1K | 192.0K | |
Non Currrent Assets Other | 77K | 56K | 53K | 60K | 54K | 51.3K | |
Net Invested Capital | 4.0M | 1.0M | 6.3M | 1.5M | (2.3M) | (2.1M) | |
Net Working Capital | 3.1M | 868K | 4.8M | (741K) | (6.1M) | (5.8M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Faron Stock Analysis
When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.